Die Übersetzung dieser Seite ist experimentell und in Entwicklung. Wir freuen uns über Ihr !

Ascendis Pharma Zukünftiges Wachstum

Future Kriterienprüfungen 5/6

Ascendis Pharma wird ein jährliches Gewinn- und Umsatzwachstum von 68% bzw. 37.3% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 68.2% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich -54.3% betragen.

Wichtige Informationen

67.9%

Wachstumsrate der Gewinne

67.9%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	24.7%
Wachstumsrate der Einnahmen	37.1%
Zukünftige Eigenkapitalrendite	-54.3%
Analystenabdeckung	Good
Zuletzt aktualisiert	31 May 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Ascendis Pharma A/S' (NASDAQ:ASND) Popularity With Investors Is Under Threat From Overpricing

Oct 05

Is Ascendis Pharma (NASDAQ:ASND) Using Debt Sensibly?

Jun 27

Analysts Are Betting On Ascendis Pharma A/S (NASDAQ:ASND) With A Big Upgrade This Week

May 05

Is Ascendis Pharma (NASDAQ:ASND) Using Debt In A Risky Way?

Feb 18

Is Ascendis Pharma (NASDAQ:ASND) A Risky Investment?

Sep 24

Ascendis Pharma: TransCon CNP Data Coming Q4

Sep 15

Ascendis Pharma seeks FDA nod for its parathyroid hormone restorer TransCon PTH

Aug 31

Ascendis Pharma Q2 results beat buoyed by strong sales of growth hormone drug Skytrofa

Aug 11

Ascendis Pharma: Institutional Buying Values Dutch Biotech Best-Now Cap-Gain Prospect

Aug 03

Here's Why Ascendis Pharma (NASDAQ:ASND) Can Manage Its Debt Despite Losing Money

Jun 10

Ascendis Pharma: Biotech Bear Provides Attractive Entry Point

May 09

Ascendis: Institutional Buying Activity Now Seen As Good Value By Market-Makers

Apr 29

Ascendis Pharma A/S' (NASDAQ:ASND) Intrinsic Value Is Potentially 51% Above Its Share Price

Feb 24

Is Ascendis Pharma (NASDAQ:ASND) In A Good Position To Invest In Growth?

Jan 07

Ascendis: Danish Biotech With Thin Audience Now Seen As Good Value By Market-Makers

Dec 30

Ascendis Pharma A/S' (NASDAQ:ASND) Intrinsic Value Is Potentially 97% Above Its Share Price

Sep 24

Gewinn- und Umsatzwachstumsprognosen

NasdaqGS:ASND - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (EUR Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	1,181	319	124	561	11
12/31/2025	719	-10	19	169	13
12/31/2024	443	-285	-174	-159	13
3/31/2024	329	-502	-423	-422	N/A
12/31/2023	267	-481	-470	-467	N/A
9/30/2023	152	-602	-573	-567	N/A
6/30/2023	119	-609	-549	-541	N/A
3/31/2023	78	-569	-524	-512	N/A
12/31/2022	51	-583	-510	-496	N/A
9/30/2022	33	-482	-493	-477	N/A
6/30/2022	19	-393	-500	-476	N/A
3/31/2022	14	-446	-490	-467	N/A
12/31/2021	8	-384	-442	-418	N/A
9/30/2021	3	-416	-409	-385	N/A
6/30/2021	5	-458	-364	-345	N/A
3/31/2021	5	-418	-306	-286	N/A
12/31/2020	7	-419	-293	-272	N/A
9/30/2020	9	-360	-248	-230	N/A
6/30/2020	8	-264	-246	-233	N/A
3/31/2020	10	-228	-191	-182	N/A
12/31/2019	13	-218	-181	-176	N/A
9/30/2019	21	-170	-167	-162	N/A
6/30/2019	19	-178	-154	-149	N/A
3/31/2019	16	-142	-168	-163	N/A
12/31/2018	11	-130	-141	-139	N/A
9/30/2018	0	-132	-129	-127	N/A
6/30/2018	1	-132	-108	-107	N/A
3/31/2018	1	-140	-111	-111	N/A
12/31/2017	2	-124	N/A	-95	N/A
9/30/2017	2	-106	N/A	-88	N/A
6/30/2017	3	-91	N/A	-78	N/A
3/31/2017	4	-73	N/A	-67	N/A
12/31/2016	5	-69	N/A	-60	N/A
9/30/2016	6	-64	N/A	-54	N/A
6/30/2016	6	-53	N/A	-50	N/A
3/31/2016	7	-55	N/A	-51	N/A
12/31/2015	8	-33	N/A	-43	N/A
9/30/2015	9	-26	N/A	-41	N/A
6/30/2015	10	-21	N/A	-32	N/A
3/31/2015	12	-8	N/A	-23	N/A
12/31/2014	14	-10	N/A	-18	N/A
9/30/2014	17	-2	N/A	-14	N/A
6/30/2014	20	0	N/A	1	N/A
3/31/2014	20	3	N/A	5	N/A
12/31/2013	20	4	N/A	6	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: ASND wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als schnelleres Wachstum als die Sparquote angesehen wird (2.4%).

Ertrag vs. Markt: ASND wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als überdurchschnittliches Marktwachstum angesehen wird.

Hohe Wachstumserträge: ASND wird voraussichtlich in den nächsten 3 Jahren rentabel werden.

Einnahmen vs. Markt: ASNDDie Einnahmen des Unternehmens (37.3% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (8.4% pro Jahr).

Hohe Wachstumseinnahmen: ASNDDie Einnahmen des Unternehmens (37.3% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: ASND wird voraussichtlich in 3 Jahren unrentabel sein.

Ascendis Pharma Zukünftiges Wachstum

Future Kriterienprüfungen 5/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Consensus EPS estimates fall by 13%, revenue upgraded

Consensus estimates of losses per share improve by 17%

Consensus revenue estimates increase by 12%

Consensus revenue estimates decrease by 11%

Consensus revenue estimates increase by 24%

Consensus revenue estimates decrease by 14%

Recent updates

Ascendis Pharma A/S Presents New Data and Updated Results from Phase 1/2 IL-Believe Trial at ASCO 2024

Ascendis Pharma A/S Announces Extension of U.S. Food and Drug Administration Review Period for TransCon PTH for Adults with Hypoparathyroidism

New minor risk - Shareholder dilution

Ascendis Pharma A/S Announces 2-Year Results from A Post-Hoc Analysis of the Company's Phase 3 PaTHway Trial

Consensus EPS estimates fall by 13%, revenue upgraded

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Ascendis Pharma A/S, Annual General Meeting, May 30, 2024

Ascendis Pharma A/S to Report Q1, 2024 Results on May 02, 2024

Ascendis Pharma A/S Announces United Kingdom's MHRA Approves YORVIPATH® (palopegteriparatide) in Great Britain for the Treatment of Adults with Chronic Hypoparathyroidism

Some Confidence Is Lacking In Ascendis Pharma A/S' (NASDAQ:ASND) P/S

Ascendis Pharma A/S Appoints Mads Bodenhoff as Senior Vice President, Finance Principal Accounting Officer

Executive VP notifies of intention to sell stock

Consensus estimates of losses per share improve by 17%

President notifies of intention to sell stock

President notifies of intention to sell stock

Full year 2023 earnings: EPS in line with analyst expectations despite revenue beat

Ascendis Pharma A/S to Report Fiscal Year 2023 Results on Feb 07, 2024

Consensus revenue estimates increase by 12%

Ascendis Pharma's Ambitious Vision 2030

Ascendis Pharma A/S Introduces Vision 2030

New minor risk - Profitability

What Ascendis Pharma A/S' (NASDAQ:ASND) 29% Share Price Gain Is Not Telling You

Ascendis Pharma A/S Announces New Analyses from Blinded and Ongoing Open-Label Extension Portions of ACcomplisH

Ascarma A/S Announces TransCon™ hGH (lonapegsomatropin) Achieved Statistically Superior Outcomes Compared to Placebo in Phase 3 foresiGHt Trial of Adults with Growth Hormone Deficiency

FDA Accepts for Review Resubmitted NDA for Transcon PTH (Palopegteriparatide) in Adult Patients with Hypoparathyroidism

President notifies of intention to sell stock

Ascendis Pharma A/S Announces European Commission Approval of YORVIPATH (Palopegteriparatide) for Treatment of Adults with Chronic Hypoparathyroidism

Ascendis Pharma A/S Resubmits NDA for TransCon™? PTH to the U.S. FDA

New minor risk - Profitability

New major risk - Negative shareholders equity

Is Ascendis Pharma (NASDAQ:ASND) Using Debt Sensibly?

New major risk - Negative shareholders equity

Ascendis Presents Updated and New Transco Il-2 ß/? Monotherapy and Combination Therapy Data Confirming Clinical Activity Across Tumor Types At Esmo 2023

Consensus revenue estimates decrease by 11%

Ascendis Pharma A/S' (NASDAQ:ASND) Popularity With Investors Is Under Threat From Overpricing

Ascendis Pharma A/S Presents Transcon Pth Data At the American Thyroid Association Annual Meeting

Key Executive notifies of intention to sell stock

Ascendis Pharma A/S Presents Results from Long-Term enliGHten Trial of TransCon hGH in Pediatric Growth Hormone Deficiency

Ascendis Pharma Launches SKYTROFA (Lonapegsomatropin) in Germany for the Once-Weekly Treatment of Children and Adolescents with Growth Hormone Deficiency

Ascendis Pharma A/S Receives Positive CHMP Opinion for Transcon PTH (Palopegteriparatide) for Adults with Chronic Hypoparathyroidism

Consensus revenue estimates increase by 24%

Independent Chairman notifies of intention to sell stock

New major risk - Financial position

Ascendis Pharma A/S Announces New Post Hoc Analysis Showing Adults with Hypoparathyroidism Treated with TransCon PTH

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Ascendis Pharma A/S to Report Q2, 2023 Results on Sep 05, 2023

Is Ascendis Pharma (NASDAQ:ASND) Using Debt Sensibly?

Aendis Pharma A/S Reports One-Year Data from Phase 3 Trial of TransCon™ PTH in Adults with Hypoparathyroidism Presented at ENDO 2023

Ascendis Pharma Showcases its Latest Endocrinology Programs, Data, and Research at ENDO 2023

Ascendis Pharma Oncology Program Update Highlights Latest Clinical Data for Product Candidates

Analysts Are Betting On Ascendis Pharma A/S (NASDAQ:ASND) With A Big Upgrade This Week

Ascendis Pharma A/S, Annual General Meeting, May 30, 2023

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Now 20% undervalued after recent price drop

Consensus revenue estimates decrease by 14%

President notifies of intention to sell stock

Is Ascendis Pharma (NASDAQ:ASND) Using Debt In A Risky Way?

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Ascendis Pharma A/S to Report Fiscal Year 2022 Results on Feb 16, 2023

President notifies of intention to sell stock

Ascendis Pharma A/S Announces U.S. Food & Drug Administration Allows to Initiate an Expanded Access Program for Its Investigational Parathyroid Hormone Replacement Therapy, Transcon PTH

President notifies of intention to sell stock

Ascendis Pharma Submits Marketing Authorization Application to the European Medicines Agency for Transcon™ PTH in Adult Patients with Hypoparathyroidism

TransCon CNP Achieves Primary Efficacy Objective, with Superiority at 100 µg/kg/week, in Ascendis Pharma’s Phase 2 ACcomplisH Trial of Children with Achondroplasia Aged 2 to 10 Years

Dose Escalation Data from transcendIT-101, Ascendis Pharma’s Phase 1/2 Trial of TransCon™ TLR7/8 Agonist in Patients with Advanced Solid Tumors, Presented at SITC 2022

Consensus forecasts updated

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Ascendis Pharma A/S Announces FDA Accepts for Priority Review Its NDA for TransCon(TM) PTH in Adult Patients with Hypoparathyroidism

Ascendis Pharma Announces Recommended Phase 2 Dose and Cohort Expansion for TranscendIT-101, A Phase 1/2 Clinical Trial of TransCon TLR7/8 Agonist in Solid Tumors